DrugPatentWatch Database Preview
Naftifine hydrochloride - Generic Drug Details
What are the generic drug sources for naftifine hydrochloride and what is the scope of freedom to operate?
Naftifine hydrochloride
is the generic ingredient in two branded drugs marketed by Taro Pharms, Tolmar, Sebela Ireland Ltd, and Taro, and is included in eight NDAs. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.Naftifine hydrochloride has three patent family members in three countries.
There are eight drug master file entries for naftifine hydrochloride. Four suppliers are listed for this compound.
Summary for naftifine hydrochloride
| International Patents: | 3 |
| US Patents: | 4 |
| Tradenames: | 2 |
| Applicants: | 4 |
| NDAs: | 8 |
| Drug Master File Entries: | 8 |
| Suppliers / Packagers: | 4 |
| Bulk Api Vendors: | 70 |
| Clinical Trials: | 9 |
| Patent Applications: | 514 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for naftifine hydrochloride |
| DailyMed Link: | naftifine hydrochloride at DailyMed |
Recent Clinical Trials for naftifine hydrochloride
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| GenZum Life Sciences LLC | Phase 3 |
| Semler Research Center Pvt. Ltd. | Phase 3 |
| Merz Pharmaceuticals, LLC | Phase 4 |
Recent Litigation for naftifine hydrochloride
Identify potential future generic entrants
District Court Litigation
| Case Name | Date |
|---|---|
| Sebela International Limited v. Taro Pharmaceuticals U.S.A., Inc. |
Pharmacology for naftifine hydrochloride
| Drug Class | Allylamine Antifungal |
Synonyms for naftifine hydrochloride
| (E)-N-Cinnamyl-N-methyl-1-naphthalenemethanamine Hydrochloride |
| (E)-N-Cinnamyl-N-methyl-1-naphthalenemethylamine hydrochloride |
| (E)-N-CINNAMYL-N-METHYL(1-NAPHTHYLMETHYL)AMINE HYDROCHLORIDE |
| (E)-N-methyl-N-(1-naphthalenylmethyl)-3-phenyl-2-propen-1-amine hydrochloride |
| (E)-N-methyl-N-(1-naphthylmethyl)-3-phenyl-2-propen-1-amine- hydrochloride |
| (E)-N-methyl-N-(1-naphthylmethyl)-3-phenyl-prop-2-en-1-amine hydrochloride |
| (E)-N-Methyl-N-(3-phenyl-2-propen-1-yl)-1-naphthalenemethanamine Hydrochloride |
| (E)-N-methyl-N-(naphthalen-1-ylmethyl)-3-phenyl-prop-2-en-1-amine hydrochloride |
| (E)-N-methyl-N-(naphthalen-1-ylmethyl)-3-phenylprop-2-en-1-amine hydrochloride |
| 1-Naphthalenemethanamine, N-methyl-N-(3-phenyl-2-propenyl)-, hydrochloride, (E)- |
| 25UR9N9041 |
| 65473-14-5 |
| A835130 |
| AB0013289 |
| AB02353 |
| AC-1120 |
| AC1NQY0T |
| AK326015 |
| AKOS015895211 |
| AN-15212 |
| API0000683 |
| AS-13296 |
| AW 105-843 |
| AW 105843 |
| AW-105-843 |
| AW-105843 |
| BC679571 |
| BCP07446 |
| C-19785 |
| C08072 |
| C1162 |
| CAS-65473-14-5 |
| CCG-213447 |
| CHEBI:7452 |
| CHEMBL1200493 |
| CS-2730 |
| D00883 |
| DSSTox_CID_25496 |
| DSSTox_GSID_45496 |
| DSSTox_RID_80915 |
| DTXSID2045496 |
| Exoderil |
| H72N880 |
| H827 |
| HMS1571E08 |
| HY-B0518A |
| I06-0253 |
| J10185 |
| LS-176455 |
| MFCD00059047 |
| MLS002154136 |
| MolPort-003-666-692 |
| N-Methyl-N-(naphthalen-1-ylmethyl)-3-phenylprop-2-en-1-amine hydrochloride |
| N-trans-Cinnamyl-N-methyl-(1-naphthylmethyl)amine Hydrochloride |
| N-trans-Cinnamyl-N-methyl-(1-napphthylmethyl)amine hydrochloride |
| NAFT-600 |
| naftifin hydrochloride, (E)-isomer |
| Naftifine (hydrochloride) |
| Naftifine HCl |
| Naftifine Hydrochloride ,(S) |
| Naftifine hydrochloride (USP) |
| Naftifine hydrochloride [USAN:USP] |
| Naftifine hydrochloride [USAN] |
| Naftifine hydrochloride, 99% |
| Naftifine hydrochloride, United States Pharmacopeia (USP) Reference Standard |
| Naftifine, HCl |
| Naftifungin |
| Naftin |
| Naftin (TN) |
| Naftin hydrochloride |
| NCGC00016908-01 |
| NCGC00179332-03 |
| NSC-760068 |
| NSC760068 |
| Pharmakon1600-01505446 |
| s3156 |
| SCHEMBL41356 |
| SCHEMBL4932462 |
| SMR001233443 |
| SN 105-843 |
| SN 105843 |
| SN-105843 |
| SR-01000838853 |
| SR-01000838853-2 |
| Suadian |
| SureCN1649698 |
| Tox21_110677 |
| Tox21_110677_1 |
| UNII-25UR9N9041 |
Paragraph IV (Patent) Challenges for NAFTIFINE HYDROCHLORIDE
| Tradename | Dosage | Ingredient | NDA | Submissiondate |
|---|---|---|---|---|
| NAFTIN | GEL;TOPICAL | naftifine hydrochloride | 204286 | 2015-02-04 |
US Patents and Regulatory Information for naftifine hydrochloride
Expired US Patents for naftifine hydrochloride
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Sebela Ireland Ltd | NAFTIN | naftifine hydrochloride | CREAM;TOPICAL | 019599-001 | Feb 29, 1988 | Start Trial | Start Trial |
| Sebela Ireland Ltd | NAFTIN | naftifine hydrochloride | GEL;TOPICAL | 019356-001 | Jun 18, 1990 | Start Trial | Start Trial |
| Sebela Ireland Ltd | NAFTIN | naftifine hydrochloride | GEL;TOPICAL | 019356-001 | Jun 18, 1990 | Start Trial | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for naftifine hydrochloride
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2014121048 | Start Trial |
| Australia | 2014212201 | Start Trial |
| Canada | 2899725 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2020 - 2021
NCE-1 Patent Challenge Dates 2020 - 2021
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2020, www.DrugPatentWatch.com.
Follow DrugPatentWatch:
